Ondansetron Aurobindo

Ondansetron, the active ingredient in Ondansetron Aurobindo, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It prevents chemotherapy‑induced, radiotherapy‑induced, and postoperative nausea and vomiting.

GNH USA supplies Ondansetron Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron is employed to control nausea and vomiting associated with chemotherapy, radiotherapy, and surgery.

Chemotherapy-induced nausea and vomiting: prevents and treats nausea and vomiting caused by cytotoxic cancer treatments. Radiotherapy-induced nausea and vomiting: reduces nausea and vomiting following radiation therapy. Postoperative nausea and vomiting: helps prevent nausea and vomiting after surgical procedures.

Common adverse reactions and rarer serious events have been reported with injectable ondansetron.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Injection site reaction: pain, erythema, or swelling at the administration site.

Serious or Rare Side Effects: - QT interval prolongation: potential cardiac arrhythmia risk. - Severe allergic reaction: anaphylaxis, rash, or angioedema. - Serotonin syndrome: agitation, hyperreflexia, or hyperthermia when combined with serotonergic agents. - Severe hypotension: marked drop in blood pressure.

Before using Ondansetron Aurobindo, consider the following precautions. - Assess cardiac risk: monitor QT interval in patients with known prolongation or cardiac disease. - Review concomitant serotonergic drugs: avoid combined use that may increase serotonin syndrome risk. - Renal impairment: use with caution in patients with severe renal dysfunction. - Hepatic impairment: adjust or monitor in patients with significant liver disease. - Pregnancy and lactation: prescribe only if the expected benefit outweighs potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medications; awareness of major and moderate interactions is essential.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive anti‑emetic effect not recommended. - Drugs that prolong QT interval (e.g., quinidine, haloperidol): increased risk of cardiac arrhythmias. - Serotonergic agents (e.g., SSRIs, MAOIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Corticosteroids (e.g., dexamethasone): may enhance anti‑emetic efficacy. - Anesthetics (e.g., propofol, volatile agents): may increase sedation when combined. - Anticholinergics (e.g., scopolamine): may affect gastrointestinal motility.